Algorithms for disease diagnostics
The present invention relates to compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including but not limited to gene expression product markers associated with cancer or genetic disorders. In particular, the present invention provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis.
1. A method for processing or analyzing a sample of thyroid tissue of a subject, comprising:
(a) sequencing nucleic acid molecules from said sample of thyroid tissue to yield data comprising one or more levels of gene expression products in said sample of thyroid tissue, which one or more levels of gene expression products correspond to a plurality of genes comprising two or more genes selected from the group consisting of: ALK, CALCA, DICER1, IGF2BP3, MET, NTRK1, NTRK3, PAX8, PTEN, PTH and THADA;
(b) using a trained algorithm in a computer to process said data from (a) to generate a classification of said sample of thyroid tissue as positive or negative for thyroid cancer at an accuracy of at least 85%, wherein said trained algorithm is trained with a plurality of training samples comprising known benign samples and known non-benign samples that is different from said sample of tissue; and
(c) electronically outputting a report that identifies said classification of said sample of thyroid tissue as positive or negative for said thyroid cancer.
2. The method of claim 1 , wherein said sample of thyroid tissue is obtained by fine needle aspiration.
3. The method of claim 1 , wherein said sample of thyroid tissue comprises two or more tissue types.
4. The method of claim 1 , wherein said data comprises ribonucleic acid (RNA) data.
5. The method of claim 4 , wherein said RNA data comprises micro RNA data.
6. The method of claim 1 , wherein said data comprises deoxyribonucleic acid (DNA) data.
7. The method of claim 6 , wherein processing of (b) comprises identifying a copy number variation or a variant in said DNA data.
8. The method of claim 1 , wherein said known non-benign samples comprise a metastatic melanoma sample, a metastatic renal carcinoma sample, a metastatic breast carcinoma sample, a metastatic B cell lymphoma sample, or any combination thereof.
9. The method of claim 1 , wherein said plurality of training samples further comprises a normal tissue sample and a plurality of samples having different tissue pathologies selected from the group consisting of follicular adenoma (FA), lymphocytic thyroiditis (LCT), nodular hyperplasia (NHP), Hurthle cell carcinoma (HC), follicular carcinoma (FC), follicular variant of papillary thyroid carcinoma (FVPTC), papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), and anaplastic carcinoma (ATC).
10. The method of claim 1 , wherein said accuracy is at least 90%.
11. The method of claim 1 , wherein said trained algorithm generates said classification at a specificity of at least about 90%.
12. The method of claim 1 , wherein said trained algorithm generates said classification at a sensitivity of at least about 80%.
13. The method of claim 1 , wherein said sample of thyroid tissue is benign for said thyroid cancer, and wherein said trained algorithm does not classify said sample of thyroid tissue as positive for said thyroid cancer.
14. The method of claim 1 , wherein said sample of thyroid tissue is malignant for said thyroid cancer, and wherein said trained algorithm classifies said sample of thyroid tissue as positive for said thyroid cancer.
15. The method of claim 1 , wherein said two or more genes are selected from the group consisting of CALCA, MET and PTH.
16. The method of claim 1 , wherein said two or more genes are selected from the group consisting of DICER1 and PTEN.
17. The method of claim 1 , wherein said two or more genes are selected from the group consisting of ALK, IGF2BP3, NTRK1, NTRK3 and THADA.
18. The method of claim 1 , wherein said two or more genes are selected from the group consisting of ALK, CALCA, DICER1, IGF2BP3, MET, NTRK1, NTRK3, PAX8, PTEN and THADA.
19. The method of claim 1 , wherein said two or more genes are selected from the group consisting of ALK, DICER1, IGF2BP3, NTRK1, NTRK3, PAX8, PTEN and THADA.
20. The method of claim 1 , further comprising providing a treatment to said subject.
21. The method of claim 1 , wherein said known benign samples and known non-benign samples comprise known malignant, known benign, and known normal samples.